Notícias e Atividades da Casi Pharmaceuticals

Casi Pharmaceuticals é uma empresa listada sob o símbolo CASI (US).

Casi Pharmaceuticals tem presença direta em 2 países.

Eles estão dentro:

• Farmacêutica67%
• Biotecnologia33%

Veja o organograma con seus 42 executivos principais

Biografias mais buscadas da Casi Pharmaceuticals

• David Cory, Chief Executive Officer
• Alexander Wu, Director
• Wei-Wu He, Director

Recentes movimentos de executivos em Casi Pharmaceuticals

• Wei-Wu He antes Executive Chairman of the Board, agora é Director  (Notícia publicada em 20 de novembro de 2025).
• Barbara Krebs-Pohl, ingressou na Companhia como Non Executive Board Member  (Notícia publicada em 27 de outubro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Casi Pharmaceuticals.

Casi Pharmaceuticals possui 1.920 concorrentes concorrentes Sanofi (França), Moderna (Estados Unidos) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• Agenus acaba de anunciar uma arrecadação de fundos de 340 milhões de dólares. (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• David Ricks - President, Chief Executive Officer and Chairman of the Board da Eli Lilly
• Richard Saynor - Chief Executive Officer da Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Casi Pharmaceuticals

• CASI Pharmaceuticals Announces First Quarter 2024 Business and Financial Results-Press Releases-CASI
• CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results-Press Releases-CASI
• Press Releases-CASI
• CASI Pharmaceuticals Reports Development Relating To Its Disputes With Juventas-Press Releases-CASI
• CASI Pharmaceuticals | CASI Pharmaceuticals Announces First Quarter 2023 Financial Results
• CASI Pharmaceuticals | CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS
• CASI Pharmaceuticals | CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022
• CASI Pharmaceuticals | CASI Pharmaceuticals Completes Redomiciliation Merger
• CASI Pharmaceuticals | CASI Pharmaceuticals And Cleave Therapeutics Announce Clinical Trial Application Approval For CB-5339 In Patients With Multiple Myeloma In China
• CASI Pharmaceuticals | CASI Pharmaceuticals’ Partner Juventas Announces New Drug Application For CNCT19 Accepted By China National Medical Products Administration
• View more press releases Close

Redes sociais sobre Casi Pharmaceuticals

• Casi Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Casi Pharmaceuticals na LinkedIn, X (Twitter) e YouTube